| Dr Frederick Smith, DO | |
|
2500 Canterbury Dr, Suite 112, Hays, KS 67601-2247 | |
| (785) 628-8221 | |
| (785) 628-3264 |
| Full Name | Dr Frederick Smith |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 2500 Canterbury Dr, Hays, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932194537 | NPI | - | NPPES |
| 100446890A | Medicaid | KS | |
| 100446890B | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 0519485 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frederick Smith, DO 2500 Canterbury Dr, Suite 112, Hays, KS 67601-2247 Ph: (785) 628-8221 | Dr Frederick Smith, DO 2500 Canterbury Dr, Suite 112, Hays, KS 67601-2247 Ph: (785) 628-8221 |
News Archive
An outbreak of gastroenteritis at an aged care facility in Adelaide is of concern as it has claimed the life of a third victim.
The Children's Learning Institute at The University of Texas Health Science Center at Houston has received a $3 million grant to teach the latest child development strategies to more than 850 infant and toddler specialists and teachers working in at-risk communities in the Lone Star State.
A new study of liver transplant centers confirms that non-Hispanic white patients get placed on liver transplant waitlists at disproportionately higher rates than non-Hispanic Black patients.
The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.
› Verified 1 days ago
Kerby Rice, PT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2514 Vine St Unit 2, Hays, KS 67601 Phone: 785-621-5888 Fax: 785-621-5890 |